CME Group Announces Key Leadership Changes in Finance and Legal Divisions
CME GROUP INC.
Subscribe to track CME
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
CME Group Inc. ($CME) filed Form 8-K announcing senior executive appointments:
• Jack Tobin appointed Managing Director, Deputy CFO effective November 2, 2026, and will become Chief Financial Officer in March 2027 (reversing previous retirement plans). • Matthew Render appointed Managing Director, Chief Accounting Officer effective November 2, 2026. • John Marchese named General Counsel succeeding Jonathan Marcus. • Transition aligns with Lynne Fitzpatrick's upcoming assumption of the CEO role in March 2027.
Comprehensive Analysis
Executive Succession & Leadership Appointments
On September 9, 2026, CME Group Inc. (NASDAQ: CME) disclosed key executive leadership transitions across its finance and legal teams pursuant to Item 5.02 of Form 8-K:
-
Chief Financial Officer Succession:
- Jack Tobin, 63, has been appointed Managing Director, Deputy Chief Financial Officer effective November 2, 2026.
- Mr. Tobin will formally assume the role of Senior Managing Director, Chief Financial Officer in March 2027, coinciding with Lynne Fitzpatrick’s transition to Chief Executive Officer.
- Mr. Tobin previously served as Chief Accounting Officer since 2015 and rescinded his previously planned October 2026 retirement to assume these responsibilities.
-
Chief Accounting Officer Appointment:
- Matthew Render, 47, will succeed Mr. Tobin as Managing Director, Chief Accounting Officer effective November 2, 2026.
- Mr. Render previously served as Deputy Chief Accounting Officer since August 2026 and was formerly Global Head of Financial Reporting, Accounting Policy & Finance Transformation at Citadel and Citadel Securities.
-
General Counsel Transition:
- John Marchese has been named General Counsel, succeeding Jonathan Marcus.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.
